Z-0350-2023 Class III Terminated

Recalled by Primus Corporation Dba Trinity Biotech — Kansas City, MO

FDA device recall Z-0350-2023 was initiated by Primus Corporation Dba Trinity Biotech on Oct 5, 2021 and is designated Class III. Reason for recall: The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. Additionally, per the firm, the unacceptable Control Level… The recall status is terminated (terminated Aug 9, 2023). Affected quantity: 182 kits.

Recall details

Product Type
Devices
Report Date
Dec 7, 2022
Initiation Date
Oct 5, 2021
Termination Date
Aug 9, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
182 kits

Product description

Trinity Biotech HbA1c (GHb) Contorls Kit, 500uL (Levels I & II), REF 01-04-0020, Part number 05-01-0040B, A1c analysis

Reason for recall

The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. Additionally, per the firm, the unacceptable Control Level 1 value results in the Analyzer generating an error code which stops further testing and nullifies associated patient samples, resulting in a delay in patient results and a potential delay in therapeutic modifications.

Distribution pattern

Turkey, India, Romania, Thailand, Vietnam, S. Korea, Peru, Pakistan Austria, UAE, Chile, Italy.

Code information

UDI/DI 0539151674808, Lot 12161

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-0350-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-0350-2023. Report a data issue: hello@regdatalab.com.